Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with an experimental immune-boosting drug called BO-112 and anti-PD-1 therapy before surgery may help the immune system fight aggressive soft tissue sarcomas. This is an early-phase investigation (preclinical plus initial clinical trial); specific study design details such as whether it was an RCT, exact sample size, and any conflicts of interest were not disclosed in the report. Source: https://medicalxpress.com/news/2026-03-triple-pre-surgery-therapy-boost.html